ClinicalTrials.gg
CompletedNCT05875727Updated Oct 24, 2024Results posted

A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.

A Phase 3 interventional study of 20-valent pneumococcal conjugate vaccine in Pneumococcal Disease, sponsored by Pfizer. Completed at 8 sites in India. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-24.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
405
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
13th of 19
405 · median 668
Started
2023
with 1 other
Phase 3
14 of 19
1 open now
Registered
15th of 19
by date
Lead sponsor
16 of 19
Pfizer

Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 13th largest by enrollment, is one of 2 that started in 2023, is one of 14 in phase 3, and was the 15th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Pneumococcal 20-Valent Conjugate Vaccine

Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety and immune response of 20vPnC in adults in India.

This study is seeking participants who:

  • are generally healthy adults of 18 years or older.
  • have not received pneumococcal vaccine.

The study will have 2 groups based on age. One group will have particpants between 18 to 49 years of age. The other group will have participants of 50 years or older.

Participants will take part in the study for about one month which includes two visits to the study clinic. Participants will receive a single dose of study vaccine (20vPnC) into the arm at visit 1 and will come to study site for a follow-up visit after about a month.

The study team will ask questions about the participant's health and blood samples will be taken in a subset of participants during the visits.

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Generally healthy participants ≥18 years of age at the time of consent.

Exclusion criteria

Exclusion Criteria:

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of 20vPnC, or to any other diphtheria toxoid-containing vaccine.
  • Known or suspected immune deficiency or suppression.
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Previous vaccination with any pneumococcal vaccine, or planned receipt of any pneumococcal vaccine through study participation.
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
405 participants (actual)

Study arms

  • Experimental
    20-valent pneumococcal conjugate vaccine

    Pneumococcal conjugate vaccine (20vPnC)

    Biological: 20-valent pneumococcal conjugate vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Local Reactions Within 7 Days After Vaccination

    Local reactions (redness, swelling, and injection site pain) at the site of investigational product administration were recorded in electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units where 1 caliper unit = 0.5 centimeter (cm). Redness and swelling were graded as mild (more than \[\>\]2.0 to 5.0 cm), moderate (\>5.0 to 10.0cm) and severe (\>10.0cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity). Exact 2-sided 95% confidence interval was based on the Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after vaccination

  2. Percentage of Participants With Systemic Events Within 7 Days After Vaccination

    Systemic events included: fever, fatigue, headache, joint pain and muscle pain. Fever was defined as an oral temperature of more than or equal to (\>=)38.0 degree Celsius (C) and was classified as \>=38.0 degree C, \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, joint pain and muscle pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Exact 2-sided 95% confidence interval was based on the Clopper and Pearson method.

    Time frame: Day 1 to Day 7 after vaccination

  3. Percentage of Participants With Adverse Events (AEs) From Vaccination to 1 Month After Vaccination

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure. Exact 2-sided 95% confidence interval was based on the Clopper and Pearson method.

    Time frame: From vaccination on Day 1 up to 1 Month after vaccination

  4. Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination to 1 Month After Vaccination

    An SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or that was considered to be an important medical event.

    Time frame: From vaccination on Day 1 up to 1 Month after vaccination

Secondary outcomes

  1. Geometric Mean Fold Rise (GMFR) of Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers From Before Vaccination to 1 Month After Vaccination

    GMFRs and 2-sided 95% confidence interval (CIs) were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ in the analysis. Evaluable immunogenicity population: Eligible participants in the immunogenicity subset who received 1 dose of the intervention with at least 1 valid immunogenicity result from the blood sample collection within 27 to 49 days after vaccination, had no other major protocol deviations as determined by the clinician.

    Time frame: From before vaccination to 1 Month after vaccination

07

Results

Posted Oct 24, 2024

Participant flow

A total of 405 participants signed the informed consent form. Two participants were screen failures and 3 were not assigned to receive study treatment and 400 participants received study treatment.

Participant flow — Overall Study
MilestoneCohort 1: 18 to 49 YearsCohort 2: >=50 Years
Started200200
Completed200200
Not completed00

Outcome measures

PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination

Local reactions (redness, swelling, and injection site pain) at the site of investigational product administration were recorded in electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units where 1 caliper unit = 0.5 centimeter (cm). Redness and swelling were graded as mild (more than \[\>\]2.0 to 5.0 cm), moderate (\>5.0 to 10.0cm) and severe (\>10.0cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity). Exact 2-sided 95% confidence interval was based on the Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination
Percentage of participantsCohort 1: 18 to 49 YearsCohort 2: >= 50 Years
Redness: Any1.0 (0.1 to 3.6)1.0 (0.1 to 3.6)
Redness: Mild0.0 (0.0 to 1.8)0.5 (0.0 to 2.8)
Redness: Moderate0.5 (0.0 to 2.8)0.5 (0.0 to 2.8)
Redness: Severe0.5 (0.0 to 2.8)0.0 (0.0 to 1.8)
Swelling: Any1.5 (0.3 to 4.3)1.5 (0.3 to 4.3)
Swelling: Mild0.5 (0.0 to 2.8)0.5 (0.0 to 2.8)
Swelling: Moderate0.5 (0.0 to 2.8)1.0 (0.1 to 3.6)
Swelling: Severe0.5 (0.0 to 2.8)0.0 (0.0 to 1.8)
Pain at the injection site: Any43.5 (36.5 to 50.7)32.0 (25.6 to 38.9)
Pain at the injection site: Mild33.5 (27.0 to 40.5)27.5 (21.4 to 34.2)
Pain at the injection site: Moderate9.5 (5.8 to 14.4)4.0 (1.7 to 7.7)
Pain at the injection site: Severe0.5 (0.0 to 2.8)0.5 (0.0 to 2.8)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination

Systemic events included: fever, fatigue, headache, joint pain and muscle pain. Fever was defined as an oral temperature of more than or equal to (\>=)38.0 degree Celsius (C) and was classified as \>=38.0 degree C, \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, joint pain and muscle pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Exact 2-sided 95% confidence interval was based on the Clopper and Pearson method.

Time frame:
Day 1 to Day 7 after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination
Percentage of participantsCohort 1: 18 to 49 YearsCohort 2: >= 50 Years
Fever: >= 38.0 degree C3.0 (1.1 to 6.4)1.5 (0.3 to 4.3)
Fever: >=38.0 to 38.4 degree C1.5 (0.3 to 4.3)0.5 (0.0 to 2.8)
Fever: >38.4 to 38.9 degree C0 (0.0 to 1.8)1.0 (0.1 to 3.6)
Fever: >38.9 to 40.0 degree C1.5 (0.3 to 4.3)0 (0.0 to 1.8)
Fever: >40.0 degree C0 (0.0 to 1.8)0 (0.0 to 1.8)
Fatigue: Any12.0 (7.8 to 17.3)12.0 (7.8 to 17.3)
Fatigue: Mild7.5 (4.3 to 12.1)8.5 (5.0 to 13.3)
Fatigue: Moderate4.0 (1.7 to 7.7)3.0 (1.1 to 6.4)
Fatigue: Severe0.5 (0.0 to 2.8)0.5 (0.0 to 2.8)
Headache: Any12.0 (7.8 to 17.3)11.5 (7.4 to 16.8)
Headache: Mild9.5 (5.8 to 14.4)9.5 (5.8 to 14.4)
Headache: Moderate2.0 (0.5 to 5.0)1.5 (0.3 to 4.3)
Headache: Severe0.5 (0.0 to 2.8)0.5 (0.0 to 2.8)
Joint pain: Any5.0 (2.4 to 9.0)4.0 (1.7 to 7.7)
Joint pain: Mild3.0 (1.1 to 6.4)2.5 (0.8 to 5.7)
Joint pain: Moderate2.0 (0.5 to 5.0)1.0 (0.1 to 3.6)
Joint pain: Severe0 (0.0 to 1.8)0.5 (0.0 to 2.8)
Muscle pain: Any14.5 (9.9 to 20.2)9.0 (5.4 to 13.9)
Muscle pain: Mild10.0 (6.2 to 15.0)7.0 (3.9 to 11.5)
Muscle pain: Moderate4.5 (2.1 to 8.4)1.5 (0.3 to 4.3)
Muscle pain: Severe0 (0.0 to 1.8)0.5 (0.0 to 2.8)
PrimaryPercentage of Participants With Adverse Events (AEs) From Vaccination to 1 Month After Vaccination

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure. Exact 2-sided 95% confidence interval was based on the Clopper and Pearson method.

Time frame:
From vaccination on Day 1 up to 1 Month after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) From Vaccination to 1 Month After Vaccination
Percentage of participantsCohort 1: 18 to 49 YearsCohort 2: >= 50 Years
Percentage of Participants With Adverse Events (AEs) From Vaccination to 1 Month After Vaccination1.5 (0.3 to 4.3)3.0 (1.1 to 6.4)
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) From Vaccination to 1 Month After Vaccination

An SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or that was considered to be an important medical event.

Time frame:
From vaccination on Day 1 up to 1 Month after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination to 1 Month After Vaccination
Percentage of participantsCohort 1: 18 to 49 YearsCohort 2: >= 50 Years
Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination to 1 Month After Vaccination00
SecondaryGeometric Mean Fold Rise (GMFR) of Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers From Before Vaccination to 1 Month After Vaccination

GMFRs and 2-sided 95% confidence interval (CIs) were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ in the analysis. Evaluable immunogenicity population: Eligible participants in the immunogenicity subset who received 1 dose of the intervention with at least 1 valid immunogenicity result from the blood sample collection within 27 to 49 days after vaccination, had no other major protocol deviations as determined by the clinician.

Time frame:
From before vaccination to 1 Month after vaccination
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFR) of Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers From Before Vaccination to 1 Month After Vaccination
Fold riseCohort 1: 18 to 49 YearsCohort 2: >= 50 Years
Serotype 124.3 (17.2 to 34.3)17.1 (10.9 to 26.9)
Serotype 38.9 (5.7 to 13.8)8.8 (5.6 to 13.8)
Serotype 415.2 (7.7 to 29.8)42.6 (22.0 to 82.6)
Serotype 514.9 (8.6 to 25.8)24.3 (13.5 to 43.7)
Serotype 6A29.8 (16.3 to 54.5)30.9 (17.5 to 54.7)
Serotype 6B8.6 (5.0 to 15.0)11.6 (6.6 to 20.5)
Serotype 7F16.0 (9.2 to 27.9)24.1 (15.6 to 37.4)
Serotype 9V4.8 (3.2 to 7.1)9.5 (5.7 to 15.8)
Serotype 145.8 (3.5 to 9.9)6.0 (3.3 to 10.9)
Serotype 18C21.4 (11.4 to 40.1)42.0 (22.4 to 78.6)
Serotype 19A15.0 (9.1 to 24.7)30.9 (18.1 to 52.6)
Serotype 19F13.1 (7.3 to 23.5)19.1 (10.5 to 35.0)
Serotype 23F46.2 (21.8 to 98.2)53.6 (28.3 to 101.4)
Serotype 818.4 (10.5 to 32.4)38.2 (22.8 to 64.2)
Serotype 10A8.4 (5.0 to 14.0)31.1 (16.1 to 59.9)
Serotype 11A3.3 (2.3 to 4.7)9.5 (5.2 to 17.3)
Serotype 12F76.1 (33.4 to 173.7)75.2 (36.7 to 154.0)
Serotype 15B48.8 (22.2 to 107.0)86.2 (40.8 to 182.1)
Serotype 22F12.6 (7.8 to 20.4)30.8 (14.2 to 67.0)
Serotype 33F8.4 (5.0 to 14.0)11.7 (7.3 to 18.6)

Adverse events

Collected over Systematic assessment: local reactions and systemic events recorded from Day 1 to Day 7 after vaccination; Non-systematic assessment: All-cause mortality, SAEs and other AEs recorded from day of vaccination (Day 1) up to 1 month after vaccination. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
20vPnC0/400 (0%)0/400 (0%)171/400 (42.8%)
Most frequent other events
Most frequent other events
Event20vPnC
Injection site pain (PAIN)General disorders151/400
Fatigue (FATIGUE)General disorders48/400
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders47/400
Headache (HEADACHE)Nervous system disorders47/400
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders18/400
Pyrexia (FEVER)General disorders9/400
Injection site swelling (SWELLING)General disorders6/400

Baseline characteristics

Safety population included all participants who received any study intervention and had safety data assessed after vaccination.

Age, Continuous
Age, Continuous(Years)Cohort 1: 18 to 49 YearsCohort 2: >= 50 YearsTotal
Mean34.7 ± 8.1858.8 ± 7.2246.7 ± 14.31
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: 18 to 49 YearsCohort 2: >= 50 YearsTotal
Female6452116
Male136148284
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: 18 to 49 YearsCohort 2: >= 50 YearsTotal
Hispanic or Latino000
Not Hispanic or Latino200200400
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: 18 to 49 YearsCohort 2: >= 50 YearsTotal
American Indian or Alaska Native000
Asian200200400
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

8 sites
  • Aakash Healthcare Private Limited
    New Delhi, Delhi 110075, India
  • Nirmal Hospital Pvt Ltd.
    Surat, Gujarat 395002, India
  • BGS Global Institute of Medical Sciences (BGSGIMS)
    Bangalore, Karnataka 560060, India
  • RajaRajeswari Medical College and Hospital
    Bangalore, Karnataka 560074, India
  • RajaRajeswari Medical College and Hospital
    Bengaluru, Karnataka 560074, India
  • Bharati Vidyapeeth (Deemed to be University) Medical College Hospital & Research Centre
    Pune, Maharashtra 411043, India
  • Jawahar Lal Nehru Hospital
    Ajmer, Rajasthan 305001, India
  • Jawahar Lal Nehru Medical College
    Ajmer, Rajasthan 305001, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Oct 2023, 1 month.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 1 month is below that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2023
First posted
May 25, 2023
StartActual
Aug 16, 2023
Primary completionActual
Oct 2, 2023
CompletionActual
Oct 2, 2023
Results first posted
Oct 24, 2024
Last update
Oct 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05875727
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 25, 2023
Start date
Aug 16, 2023
Primary completion
Oct 2, 2023
Completion
Oct 2, 2023
Results posted
Oct 24, 2024
Last update
Oct 24, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine

Start the discussion